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and	 thirty-two	 (70.3%)	of	 the	330	patients	 answered	 “RMOG	every	 time”	 and	98	
(29.7%)	of	them	did	“RMOG	sometimes”	and	did	“no	RMOG.”	There	was	a	difference	






after	 inhalation	for	patients	receiving	 inhaled	medication	 is	still	necessary.	Our	re-
sults	suggest	that	it	is	better	to	store	inhalers	in	places	where	there	is	easy	access	to	
tap	water	used	for	RMOG.
K E Y W O R D S
allergy,	bronchial	asthma,	chronic	obstructive	respiratory	disease,	rinsing	of	oropharynx,	
storage	place	of	inhaler
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1  | INTRODUC TION
At	 present,	 inhaled	 corticosteroid	 (ICS),	 long-acting	 beta-agonist	
(LABA),	combination	of	ICS	and	LABA	(ICS/LABA),	long-acting	mus-
carinic	 antagonist	 (LAMA),	 and	 combination	 of	 LAMA	 and	 LABA	








is	 recommended	 to	 remove	 inhaled	 drugs,	 such	 as	 ICS,	 deposited	
on	the	oropharyngeal	mucosa.6	In	addition,	dry	mouth	is	one	of	the	






inhaled	medicine.	Therefore,	 in	 Japan,	physicians	 in	 several	hospi-

















on	a	difference	 in	disease	or	drugs.	 In	 this	study,	patient	behavior	
was	evaluated	from	the	viewpoint	that	it	is	desirable	to	gargle	after	
inhalation.
In	 clinical	 practice,	 there	 has	 been	 no	 report	 that	 examined	
the	 proportion	 of	 patients	 performing	 RMOG	 while	 consider-
ing	 the	 storage	 location	 of	 the	 inhaler.	 To	 clarify	 the	 proportion	
of	patients	performing	RMOG	after	 inhalation	in	clinical	practice,	
we	performed	a	survey	at	three	tertiary	hospitals	in	Japan.	In	ad-
dition	 to	 this,	we	 investigated	where	 the	 inhaler	was	 stored,	and	
whether	 there	 was	 relationship	 between	 storage	 location	 and	 if	
patients	were	 performing	 the	 RMOG.	 The	 findings	 of	 this	 study	
may	provide	useful	information	to	mitigate	the	local	AEs	of	inhaled	
medications.
2  | MATERIAL S AND METHODS
2.1 | Patients and methods
This	was	 a	 cross-sectional	 audit	was	 conducted	 at	 three	hospitals	
(Mito	Medical	 Center,	 University	 of	 Tsukuba-Mito	 Kyodo	General	




in	 charge	of	 treatment,	 but	 rather	 by	medical	 aids	without	 a	 con-
flict	of	interest	with	patients	to	be	interviewed.	At	outpatient	visit,	



































agonist;	 LAMA,	 long-acting	 muscarinic	 antagonist;	 LAMA/LABA,	
combination	of	LAMA	and	LABA;	RMOG,	rinsing	of	the	mouth	and	the	
oropharynx	by	gargling;	SABA,	short-acting	beta-agonist.
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patients	 were	 asked	 two	 questions:	 (a)	 whether	 they	 did	 “RMOG	




















During	 the	 study	 period,	 all	 the	 consecutive	 330	 patients	 with	
bronchial	 asthma	 or	 COPD,	 who	 agreed	 with	 the	 participation	 in	
this	study,	were	 included.	The	patient	characteristics	are	shown	in	
Table 1. Two hundred and fifteen were male and 115 were female. 






















patients	 treated	with	 LAMA	and	other	drug-containing	 inhalation.	
In	 addition,	 the	 proportion	 of	 “RMOG	 every	 time”	 was	 higher	 in	










Number of patients who answered they did
“RMOG every time”
“RMOG sometimes” or 
“no RMOG” P‐value
Age	(median,	range),	(y) 73,	26-93 71,	41-95 0.4046
Gender,	M/F 134/98 81/17 0.0001
Diagnosis
Asthma/COPD 182/50 40/58 0.0001
ICS-containing	drugs




















and	 patients	 treated	 with	 ICS-containing	 inhalation,	 respectively.	
There	 was	 a	 significant	 difference	 in	 the	 inhaler	 storage	 place	 in	
these	patients.
Table	5	shows	the	proportion	of	“RMOG	every	time”	and	“RMOG	
sometimes”	 or	 “no	 RMOG”	 in	 108	 patients	 with	 COPD.	 “RMOG	
















of	 “RMOG	every	 time”	was	 significantly	 higher	 in	 female	 patients	
than	that	of	male	patients	in	both	diseases.	But	age	of	the	patients	
had	nothing	to	do	with	performing	“RMOG	in	both	diseases.”	Fourth,	
with	 regard	 to	 the	 storage	 location	of	 inhaler,	we	 found	 that	 per-










related	with	 the	volume	of	 saliva	 secreted	and	 the	dose	of	 ICS	ad-




on	 local	adverse	effects	caused	by	 inhaled	drugs.23,24	 In	a	study	by	
Kajiwara	et	al23	with	892	patients	with	bronchial	asthma,	the	absence	
of	RMOG	after	 ICS	was	associated	with	 topical	adverse	symptoms.	










were	 female	 patients	 in	 our	 study.	 In	 the	 article	 by	Malimard	 et	al,	
ICS	was	administered	 to	all	patients,	but	18	of	108	COPD	patients	
were	 received	 ICS	 including	 inhalation	 in	 our	 study.	 The	 causes	 of	
the	differences	are	beyond	our	knowledge,	but	we	suppose	that	they	
might	be	related	to	these	backgrounds	of	the	study	subjects.	Taking	
their	 results	 into	 consideration,	 in	 order	 to	 lower	 the	 frequency	 of	
local	adverse	effects,	it	can	be	necessary	to	start	guidance	of	RMOG	














was	higher	 in	patients	who	stored	 inhalers	 in	a	room	with	running	





Age	(median,	range),	(y) 71,	26-95 73,	41-89 0.0194
Gender,	M/F 117/105 98/10 0.0001
Diagnosis
Asthma/COPD 182/50 40/58 0.0001
ICS-containing	drugs














oid,	 LAMA,	 long-acting	 muscarinic	 antagonist,	 RMOG,	 rinsing	 of	 the	
mouth	and	the	oropharynx	by	gargling.






target	 group	of	patients	 and	 to	properly	 instruct	 them.	The	 infor-
mation	on	the	relationship	between	the	storage	place	of	inhaler	and	
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Number of patients who answered they did
“RMOG every time”
“RMOG sometimes” or 
“no RMOG” P‐value
Age	(median,	range),	(y) 72,	26-93 70,	41-95 0.6244
Gender,	M/F 87/95 30/10 0.0026
ICS-containing	drugs















Number of patients who answered they did
“RMOG every time”
“RMOG sometimes” or 
“no RMOG” P‐value
Age	(median,	range),	(y) 74,	46-87 72,	41-89 0.3845
Gender,	M/F 47/3 51/7 0.3345
ICS-containing	drugs
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